ERBB2 and ovarian cancer: In a phase I/II single-arm trial (n = 15) of HER2-positive solid tumors (including breast and ovarian cancers), infusion of HER2-directed CAR-NK cells led to disease stabilization in certain patients, with no significant CRS or neurotoxicity observed [40].